PROTALIX BIOTHERAPEUTICS INC

PLXNYSE AMERICAN

🏆 #2771 by market capEarnings Aug 12US Equity

$2.43▼ $0.05 (−2.02%)

Live

1h—

24h▼ 2.0%

7d—

14d—

30d—

1y—

🏦Market Cap

$196M

Small Cap

📈Revenue Growth (YoY)

+27.8%

High Growth

📊Gross Margin

70.0%

High

💵FCF Margin

30.0%

Strong

⚖️P/S Ratio

2.6x

Cheap

Otter Score

Weak

No chart data available for PLX.

Trading Snapshot

Day Range: $2.40 – $2.45
52-Week Range: $1.46 – $3.19
Volume: $3.34B
Avg Volume: $2.44B
Shares Outstanding: 80.6M
Next Earnings: Sep 10, 2026

Fundamentals Snapshot

Annual Revenue: $53M
Last Q Revenue: $34M
P/E Ratio: 12.9
P/S Ratio: 2.6x
EPS (TTM): $0.18
Dividend Yield: —

Why Investors Own PLX

✓High-growth profile — revenue up +12.2% YoY with expanding US Equity exposure.
✓Healthy economics — 53% gross margin and 29% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$53M▲ +13.9% YoY

Gross Margin (TTM)

52.5%▲ +1.4% YoY

Operating Income (TTM)

$9M▲ +13.9% YoY

Free Cash Flow (TTM)

$15M▲ +13.9% YoY

About PROTALIX BIOTHERAPEUTICS INC

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.

🦦